Genzyme's Manufacturing Problems
Executive Summary
Genzyme looks increasingly vulnerable after the temporary closure of its Allston manufacturing facility resulted in shortages of one of its primary products, Cerezyme. Analysts remain divided on the long-term consequences, but there's no denying the the gaffes have created an opening for medicines from competitors Shire and Protalix.
You may also be interested in...
Sanofi Pursues Genzyme, But For How Long?
Sanofi-Aventis SA's hostile bid for Genzyme Corp. creates difficult choices for the Cambridge, Mass.-based biotech's investors. Do they continue to trust Genzyme's management team, despite its track record of missteps and overly enthusiastic and frequently wrong guidance? Or should they cash out now while there is a clear and certain opportunity?
Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.
Genzyme, J&J Manufacturing Troubles Highlight The Importance Of Quality Systems
Experts say robust quality systems, if taken to heart, can play a key role in preventing and recovering from manufacturing failures like the ones that have struck Genzyme and Johnson & Johnson in recent months.